Paper Details

  1. Home
  2. Paper Details

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

Author: , AkdoganMeral, CakalogluYilmaz, FerenciPeter, HansenBettina E, JanssenHarry L A, OrmeciNecati, Raptopoulou-GigiMaria, RijckborstVincent, SimonKrzysztof, TabakFehmi, VerheyElke, ZondervanPieter E, ter BorgMartijn J, van VuurenAnneke J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combination therapy with peginterferon alpha-2a and ribavirin did not improve the sustained response rate in HBeAg-negative chronic hepatitis B patients compared to monotherapy with peginterferon alpha-2a. Both treatment groups showed a decrease in serum HBV DNA and HBsAg levels during treatment, but HBV DNA levels relapsed after treatment discontinuation.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates. METHODS: Overall, 138 HBeAg-negative chronic hepatitis B patient...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/ajg.2010.186

データ提供：米国国立医学図書館（NLM）

Peginterferon Alpha-2a and Ribavirin: A Treatment Trial for Chronic Hepatitis B

The desert of chronic hepatitis B (CHB) is a challenging landscape, where antiviral therapies are essential for managing the disease. This study, like a clinical trial navigating a vast and complex desert, investigated the efficacy of peginterferon alpha-2a with or without ribavirin in HBeAg-negative CHB patients. The researchers, guided by the need for effective treatment strategies, found that while both monotherapy and combination therapy with ribavirin led to a decline in viral load and liver inflammation, the sustained response rate remained limited. The study highlights the challenges in achieving sustained viral suppression in HBeAg-negative CHB patients.

A Limited Oasis: Challenges in Sustained Response

This study, like a traveler encountering a temporary oasis in a vast desert, reveals the challenges in achieving sustained viral suppression in HBeAg-negative CHB patients. The researchers found that while both monotherapy with peginterferon alpha-2a and combination therapy with ribavirin resulted in a decline in viral load and liver inflammation, the sustained response rate was limited. This underscores the need for continued research to explore more effective treatment strategies that can achieve long-term viral suppression and prevent relapse in this patient population.

Navigating the Desert of CHB: Seeking a Sustainable Path

This research, like a road sign in a vast desert, highlights the importance of ongoing research in CHB management. The researchers found that while peginterferon alpha-2a and ribavirin can effectively reduce viral load and liver inflammation, the challenge lies in achieving sustained viral suppression. This reinforces the need for continued efforts to develop novel therapies that can effectively manage CHB and prevent relapse. The desert of CHB is a complex and ever-changing landscape, but with continued research and innovation, we can find sustainable paths to better health and well-being for those living with this disease.

Dr.Camel's Conclusion

This study, like a desert expedition encountering a temporary oasis, reveals the challenges in achieving sustained response to treatment for HBeAg-negative CHB patients. The findings underscore the need for continued research to develop more effective therapies that can achieve long-term viral suppression and prevent relapse. The desert of CHB is a challenging landscape, but with continued dedication and innovation, we can find sustainable paths to better health and well-being for those living with this disease.
Date :
  1. Date Completed 2010-09-14
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

20461068

DOI: Digital Object Identifier

10.1038/ajg.2010.186

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.